Cite
Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
MLA
Bennett, Jason W., et al. “Phase 1/2a Trial of Plasmodium Vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.” PLoS Neglected Tropical Diseases, vol. 10, no. 2, Feb. 2016, pp. 1–16. EBSCOhost, https://doi.org/10.1371/journal.pntd.0004423.
APA
Bennett, J. W., Yadava, A., Tosh, D., Sattabongkot, J., Komisar, J., Ware, L. A., McCarthy, W. F., Cowden, J. J., Regules, J., Spring, M. D., Paolino, K., Hartzell, J. D., Cummings, J. F., Richie, T. L., Lumsden, J., Kamau, E., Murphy, J., Lee, C., Parekh, F., & Birkett, A. (2016). Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy. PLoS Neglected Tropical Diseases, 10(2), 1–16. https://doi.org/10.1371/journal.pntd.0004423
Chicago
Bennett, Jason W., Anjali Yadava, Donna Tosh, Jetsumon Sattabongkot, Jack Komisar, Lisa A. Ware, William F. McCarthy, et al. 2016. “Phase 1/2a Trial of Plasmodium Vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.” PLoS Neglected Tropical Diseases 10 (2): 1–16. doi:10.1371/journal.pntd.0004423.